Bridgebio Pharma Inc
BBIONASDAQStock · Data from SEC EDGAR 13F · Held by 11 of 87 tracked investors
Bridgebio Pharma Inc at a glance
An overview of the financial statements, in plain language. Switch to the advanced view for charts.
- Valuation15
- Growth95
- Profitability5
- Quality25
- Debt15
- Stability19
- ✓Revenue grew 86.3% a year over 3 years.
- ✓The analysts' average target is 55% above the price.
Is the stock expensive?
ExpensiveThe company has no earnings, so the P/E cannot be calculated.
- P/E
- –
- P/S
- 19.0×
- EV/EBITDA
- -33.8×
Is the company growing?
GrowingRevenue over 3 years grew 86.3% a year. Last year 120.4%.
Does it make money?
Loss-makingEarnings results
| Quarter | Reported | EPS | Analyst estimate | Surprise |
|---|---|---|---|---|
| Jun 2026 | 10 Aug 2026 | -0.78 | -0.64 | -21.9% |
| Mar 2026 | 7 May 2026 | -0.84 | -0.70 | -20% |
| Dec 2025 | 24 Feb 2026 | -1.00 | -0.75 | -33.3% |
| Sep 2025 | 29 Oct 2025 | -0.95 | -0.88 | -8% |
EPS is earnings per share. The surprise is the difference against the analysts' consensus. Source: Nasdaq, in dollars.
Chart BBIO
Insider purchases
last 90 days, SEC Form 4Which investors hold this stock
11AH Andreas Halvorsen Viking Global Investors | 2.11% |
RD Ray Dalio Bridgewater Associates | 0.14% |
SC Steven Cohen Point72 Asset Management | 0.13% |
JS Jim Simons Renaissance Technologies | 0.09% |
KG Ken Griffin Citadel Advisors | 0.03% |
IE Israel Englander Millennium Management | 0.01% |
PT Paul Tudor Jones Tudor Investment Corp | 0.01% |
KF Ken Fisher Fisher Investments | 0.01% |
Ns Norský státní fond Norges Bank | 0.01% |
Šn Švýcarská národní banka Swiss National Bank | 0.01% |
CA Cliff Asness AQR Capital Management | 0% |
Frequently asked questions
How much is Bridgebio Pharma Inc (BBIO) stock?
Bridgebio Pharma Inc shares trade at $69.37, +1.79% over the last trading day. The price is delayed.
What is the market cap of Bridgebio Pharma Inc?
The market cap of Bridgebio Pharma Inc is about $13.6B.
Which big investors hold Bridgebio Pharma Inc?
According to the latest 13F filings, 11 of 87 tracked investors hold Bridgebio Pharma Inc, for example Andreas Halvorsen, Ray Dalio, Steven Cohen.
When will Bridgebio Pharma Inc report its next results?
The next earnings report of Bridgebio Pharma Inc is expected on 29 Oct 2026.
Source: SEC EDGAR 13F-HR (quarterly filings). The data is indicative and is not investment advice.